CoChat
Sign Up
Cited by 81Nutrition and Health in AgingHormonal and reproductive studiesProstate Cancer Treatment and Research

The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer

Boxer, R. S., Kenny, A. M., Dowsett, R., Taxel, P.·2005·The Aging Male
DOI 10.1080/13685530500361226
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To evaluate body composition changes, specifically skeletal muscle mass, in men receiving androgen deprivation with luteinizing-hormone releasing hormone-agonist (LHRH-A) for prostate cancer (PCa) in comparison with healthy controls. DESIGN: Retrospective analysis of body composition changes in men with prostate cancer receiving LHRH-A therapy from 2 clinical trials compared to men without prostate cancer serving as a placebo-control in another clinical trial. SETTING: Clinical Research Center in Connecticut. PARTICIPANTS: Thirty men (> 60 years) receiving 6 months of LHRH-A therapy for PCa were compared to a healthy group of 25 men without PCa. MEASUREMENTS: Appendicular skeletal muscle/height2 (ASM/ht2), lean and fat mass were assessed by dual energy x-ray absorptiometry. Total testosterone levels were assessed by enzyme immunoassay. RESULTS: At baseline, 12/30 (40%) of the treatment group and 7/25 (28%) of the control group (p = 0.11) met criteria for sarcopenia. There were no differences between control groups in ASM/ht2 or lean mass. The LHRH-A group had a higher percent body fat than the control group, 29.8 +/- 6.3 versus 26.3 +/- 4.6 (p = 0.02). ASM/ht2 and lean mass decreased in the LHRH-A group from 7.5 +/- 0.9 kg to 7.3 +/- 0.9 kg (-2.3% +/- 0.03; p < or = 0.001) and 53.5 +/- 5.4 kg to 52.3 +/- 5.3 kg (-2.1% +/- 0.03; p < or = 0.001), respectively. There was no muscle loss in the control group. At 6 months, the LHRH-A group had increased percent body fat from 29.8 +/- 6.4 to 32.2 +/- 5.8 (9.5% +/- 0.13; p < or = 0.001), whereas the control group had decreased in percent body fat from 26.6 +/- 4.6 to 25.3 +/- 5.0 (-3.8% +/- 0.08; p = 0.02). CONCLUSIONS: Men undergoing LHRH-A treatment for PCa decreased appendicular skeletal muscle and lean tissue and increased body fat within 6 months of initiation of therapy. Lifestyle changes or medical interventions to minimize the effects of androgen deprivation therapy for PCa deserve investigation.

Integrity signals

Registry

Crossref · 10.1080/13685530500361226

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • After 6 months of androgen-deprivation therapy, older men have decreased appendicular skeletal muscle, decreased lean tissue, and increased body fat compared with untreated controls.

    “After 6 months of treatment, androgen-deprived older men have decreased appendicular skeletal muscle, decreased lean tissue, and increased body fat compared with untreated controls.79”

    From Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases (2014) · cites this paper as [79]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Boxer, R. S., Kenny, A. M., Dowsett, R., & Taxel, P.
Affiliations
UConn Health (US)
ORCID
Boxer, R. S.
Venue
The Aging Male
Publisher
Informa UK Limited
Published
2005-01
Volume
8
Issue
3-4
Pages
207-212
ISSN
  • 1368-5538 (ISSN-L)
  • 1473-0790
DOI
10.1080/13685530500361226
OpenAlex
W2032157624
Cited by
81
References
44
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 7 · 2019: 6 · 2018: 5 · 2017: 4 · 2016: 7 · 2015: 4 · 2014: 7 · 2013: 4 · 2012: 4
FWCI
2.61
Type
journal article
Language
en
Open access
closed
Locations
  • The Aging Male (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Brookdale Foundation
  • Patrick and Catherine Weldon Donaghue Medical Research Foundation
  • National Institutes of Health (5p60ag013631-05)
  • National Institute on Aging (5P60AG13631)
  • National Center for Research Resources (M01RR006192, M01 RR 06192)
Topics
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
Keywords
androgen deprivation therapy, GnRH agonist, prostate cancer, localized prostate cancer, older men, body composition, skeletal muscle mass, sarcopenia, fat mass, lean body mass, testosterone, muscle mass loss, fat gain, dual-energy X-ray absorptiometry, appendicular skeletal muscle mass, bone mineral density
MeSH terms
Aged, Androgen Antagonists, Body Composition, Humans, Gonadotropin-Releasing Hormone, Male, Middle Aged, Prostatic Neoplasms, Receptors, LHRH, Retrospective Studies, Time Factors, Case-Control Studies, Muscle, Skeletal, Adiposity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review